New drug combo aims to control tough leukemia with fewer side effects
NCT ID NCT06782542
Summary
This study is testing a combination of three drugs (olutasidenib, venetoclax, and azacitidine) for adults newly diagnosed with a specific type of acute myeloid leukemia (AML) that has an IDH1 mutation. The main goals are to see if this combination is safer and works better than the standard intensive chemotherapy. It will involve about 16 participants to measure side effects and how many people achieve remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.